Boston-based Stealth Biotherapeutics reported that its Phase III MMPOWER-3 clinical trial of elamipetride failed to meet its primary endpoint. The trial was evaluating the effectiveness of elamipetride in patients with primary mitochondrial myopathy (PMM).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,